TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06126653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose ARD-501
Description: Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose ARD-501
Description: Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose ARD-501
Description: Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titratable, liquid formulation, taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titratable, liquid formulation, taken orally.
Study: NCT05636514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
Description: Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily
Study: NCT06127784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing counselling session
Description: Individually tailored treatment summary and survivorship care plan provided within a 1-hour 1 hour counseling session with a clinical nurse specialist
Study: NCT04376242

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: use of virtual reality
Description: The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of virtual reality
Description: The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: use of standard technology
Description: the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of standard technology
Description: the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
Study: NCT06075654

Intervention type: OTHER
Intervention: no intervention it is considered (Epidemiological Study)
Description: It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups

Intervention type: OTHER
Intervention: no intervention it is considered (Epidemiological Study)
Description: It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
Study: NCT06092034

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RP-A501
Description: RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
Study: NCT05665608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Study: NCT04662723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: To reduce the progression of renal damage in IgAN Patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: To reduce the progression of renal damage in IgAN Patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin sytem blockers
Description: To reduce the progression of renal damage in IgAN Patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-angiotensin sytem blockers
Description: To reduce the progression of renal damage in IgAN Patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-angiotensin sytem blockers
Description: To reduce the progression of renal damage in IgAN Patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin sytem blockers
Description: To reduce the progression of renal damage in IgAN Patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibitor
Description: To reduce the progression of renal damage in IgAN Patients
Study: NCT06165237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR6001-1
Description: One tablet administered alone, Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR6001-2
Description: One tablet administered alone, Once a day
Study: NCT04806321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project SOLVE
Description: This 30-minute, self-guided, digital program is designed to help adolescents solve, rather than be overwhelmed by, everyday problems.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Project SUCCESS
Description: This 30-minute, self-guided, digital program is designed to help adolescents develop study skills.
Study: NCT05621850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
Study: NCT06056453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: IPT group-virtual
Study: NCT06117553

Intervention type: PROCEDURE
Intervention: thorough flushing
Description: The thorough flushing strategy refers to the thorough flushing of all liquid and foam accumulation areas during the inspection. Make all liquid accumulation parts in the intestinal cavity free of aspiratable liquid retention
Study: NCT04408664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate
Description: Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
Study: NCT04993872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy Tab
Description: Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
Study: NCT04140721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo pill identical to moxonidine administered for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo pill identical to moxonidine administered for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine Pill
Description: Moxonidine pill administered for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine Pill
Description: Moxonidine pill administered for 4 weeks
Study: NCT06192238

Intervention type: PROCEDURE
Intervention: adrenal venous sampling
Description: Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Study: NCT06277570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: Neuromuscular Electrical Stimulation (NMES) is a non-invasive method that activates intramuscular nerve branches and produces visible contractions through surface electrodes placed on skeletal muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Superimposed NMES
Description: Superimposed NMES technique is the use of NMES with voluntary muscle contraction.
Study: NCT05136079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic lymphaticonvenous anastomosis
Description: Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
Study: NCT05208827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo(not contain vitamin D)
Description: Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
Study: NCT05602506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50 mg/200 mg/25 mg film-coated tablets
Description: The duration of the study treatment will be 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50 mg/200 mg/25 mg film-coated tablets
Description: The duration of the study treatment will be 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50 mg/200 mg/25 mg film-coated tablets
Description: The duration of the study treatment will be 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biktarvy 50 mg/200 mg/25 mg film-coated tablets
Description: The duration of the study treatment will be 48 weeks.
Study: NCT05028829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Oral administration of atorvastatin 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo
Study: NCT05082337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAVVY guidewire
Description: The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
Study: NCT04697290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20 Dual-CAR-T cells
Description: CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.
Study: NCT05298683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Description: Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine (or equivalent)
Description: Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (or equivalent)
Description: Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
Study: NCT06508060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neosensory Wristband
Description: The Neosensory wristband consists of four vibratory motors built into the strap of the wristband (Figure 1a). The motors are linear resonant actuators (LRAs), vibrating at 175 Hz, capable of rising from 0 to 50% of their intensity within 30 ms. The motor intensity can be controlled with an eight bit resolution, meaning each motor can be controlled at 256 different intensities. At the highest intensity, each motor vibrates at 1.7 GRMS. The motors are separated from one another at a distance of 18.2 mm and 19.2 mm for the small and large wristband sizes, respectively (center-to-center distances).~The top of the wristband is a module that contains the power button, user setting buttons, a microphone, and a microcontroller. Bluetooth communication is used to create the corresponding vibrations on the wristband. While the study app plays the tones, it also sends a Bluetooth command to the wristband such that the wristband vibrates in the appropriate illusory location.

Intervention type: OTHER
Group type: OTHER
Intervention: Tones only
Description: Tones will be played through an app
Study: NCT05565170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured ICT-assisted multimodal lifestyle intervention
Description: The structured lifestyle intervention programme, partly tailored and personalised to individual needs, covers the following domains: physical activity, nutrition, cognitive activity, cardiovascular risk management, social interaction, sleep, and relaxation / stress management. The programme includes regular scheduled in-person sessions (group-based + individual) which are supported with independent digital activities in the LETHE App. The App has features such as e.g., a cognitive training programme, on-demand exercise videos, calendar to schedule activities, advice and educational material, group chat, and possibility to set and monitor goals and self-monitor risk factors such as e.g., blood pressure.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self-guided multimodal lifestyle intervention
Description: Participants are advised to build their own healthy lifestyle programme based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits and through the simplified version of the LETHE app. The control group app does not include any structured / scheduled activities or personalised content.
Study: NCT04552171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to Game Plan app and 24-hour helpline
Description: Game Plan is a web-based application that helps users reflect on their risk for HIV and level of alcohol use, and if interested, make a plan for reducing their sexual risk or drinking.
Study: NCT05259423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Education Program
Description: Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Education Program
Description: Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical Education Program
Description: Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical Education Program
Description: Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
Study: NCT06189859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic submucosal dissection using SPRAY COAG mode
Description: After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Spray coag mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic submucosal dissection using Precisect mode
Description: After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Precisect mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
Study: NCT05994638

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)
Description: Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3
Study: NCT06112353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine Injectable Solution
Description: Examine GI-2 recovery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex injection
Description: Examine GI-2 recovery
Study: NCT05953155

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Each educational class will last for 1 hour and consists of evidence-based information about low back pain, including, for example, self-management strategies, pain education, reassurance and common misconceptions about back pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants in the intervention group will receive, in addition to the educational classes, a course of yoga program led by certified yoga instructors. The program consists of a 60-min group session with up to 10 participants, delivered twice a week for 12 weeks.
Study: NCT06003075

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab and Chemotherapy
Description: 3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab and Chemotherapy
Description: 3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Induction Surgery
Description: Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles